Yubin Kang, MD
Cellular Therapy Specialist, Hematologic Oncologist, Hematologist (Malignant), Stem Cell Transplant Specialist
My Locations
Part of the Duke Cancer Institute
About Me
As a physician and scientist, my ultimate goal is to translate research findings from bench to beside to improve patient care. I focus my research and clinical work on treating blood and bone marrow cancers. Most of the patients in my clinic are blood and bone marrow transplant patients and patients with plasma cell diseases such as multiple myeloma, amyloidosis, POEMS syndrome, and Waldenstrom's macroglobulinemia. The research interests in my lab are on the development of new approaches to enhance hematopoietic stem cell engraftment and reconstitution following blood and bone marrow transplant.
- Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute 2013
Call for an Appointment
Areas of Expertise
- Light or Heavy Chain Deposition Disease
- POEMS Syndrome
- Allogeneic Transplant
- Autologous Transplant
- Multiple Myeloma
- Syngeneic Transplant
- Waldenstrom's Macroglobulinemia
- Amyloidosis
- Adult Bone Marrow Transplant
- Multiple Sclerosis
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
Clinical Focus and Research
My lab research is focused on two areas. The first area is to define the genes and molecules in the bone marrow stem cells and in the bone marrow micro-environment that regulate hematopoietic stem cell function and number. We are particularly interested in the roles of CXCR4 and Pim kinases in hematopoiesis. The second area of my research is to identify molecules and pathways that can be used as biomarkers for treatment responses and as therapeutic targets for the treatment of multiple myeloma.
-
CARTITUDE-6 (Multiple Myeloma)IRB# PRO00115135 , NCT# NCT05257083
-
A Phase 2, Study to Evaluate Prophylactic Interventions on Talquetamab-related oral toxicityIRB# PRO00115711 , NCT# NCT06500884
- A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplan awarded by Stitching European Myeloma Network 2024 - 2029
- An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458;anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER- awarded by Regeneron Pharmaceuticals, Inc. 2024 - 2029
- Zhu, Xiaoyi, Qiang Huang, Laiming Jiang, Van-Tu Nguyen, Tri Vu, Garth Devlin, Jabbar Shaima, et al. “Longitudinal intravital imaging of mouse placenta.” Sci Adv 10, no. 12 (March 22, 2024): eadk1278. https://doi.org/10.1126/sciadv.adk1278.
- Kumar, Shaji K., Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, et al. “Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 22, no. 1D (January 2024): e240001. https://doi.org/10.6004/jnccn.2024.0001.
- Kumar, Shaji K., Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, et al. “Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 21, no. 12 (December 2023): 1281–1301. https://doi.org/10.6004/jnccn.2023.0061.
- Kang, Y., and N. J. Chao. “Strategies to enhance hematopoietic stem cell engraftment following transplantation.” In Novel Developments in Stem Cell Mobilization Focus on CXCR4, 439–56. Springer Science & Business Media, 2012.
- Kang, Y., and N. Chao. “Immune reconstitution.” In Hematopoietic Stem Cell Transplantation A Handbook for Clinicians, edited by J. R. Wingard, D. Gastineau, H. Leather, E. C. Snyder, and Z. M. Szczepiokowski, 181–96. Bethesda, MD: AABB Press, 2010.
- Kang, Y., and J. He. “Interleukin-4.” In A Handbook of Human Cytokines, edited by J. He and D. X. Wang, 97–112. China: Tong Zi University Press, 1996.
- Xiang, Kun, Ergang Wang, John Mantyh, Gabrielle Rupprecht, Marcos Negrete, Golshid Sanati, Carolyn Hsu, et al. “Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.” In Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 11:e2303379, 2024. https://doi.org/10.1002/advs.202303379.
- Kang, Yubin, Xiaobei Wang, Jian Wu, Shaima Jabbar, Chongming Tom Jiang, Xiling Shen, and Besim Ogretmen. “Inhibition of Sphingosine Kinase 2 Enhances Immunotherapy in Mouse Model of Multiple Myeloma.” In Blood, 142:876–876. American Society of Hematology, 2023. https://doi.org/10.1182/blood-2023-186965.
- Wang, Xiaobei, Parker Mathews, Krista Rowe Nichols, Shaima Jabbar, Johanna Jensen, Jonathan Huggis, Daniel Schrum, et al. “Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- OrPro Therapeutics Inc
- PSI Pharma Support American Inc
- Xilis, Inc